獸醫 動物科技 試劑 耗材
產程(Bulk)需求
Protein
製藥等級耗材(Pharmaceutical grade)
Antibiotics
Stem Cell
Hot!!! Top sales 10
Screening Libraries 篩選庫
Inhibitors 抑制劑
過濾設備
研究用抗癌藥物
基礎分生
實驗耗材
初級抗體
二級抗體
Normal Serum
ELISA KIT
IHC KIT
Proteomics
生化分析
化學藥品
BUFFER
Smart Solution
實驗儀器
電泳配件
水質檢測
細胞生物
In-Vitro Diagnostic   體外診斷試劑組
委託服務
中草藥標準品
GMP cytokine
GMP Medium
GMP antibody
GMP Antigens
 

首頁 > 最新消息

Selleckchem分子免疫療法單株抗體 新品預告上市…

分子免疫療法是利用單株抗體與T細胞上的特定分子結合,以阻斷腫瘤細胞的抑制訊號,使T細胞發揮殺死癌細胞的功能,這些藥物稱為免疫檢查點抑制劑(checkpoint inhibitor)或抑制型抗體 (inhibitor antibody)

 

 

                                      CTLA-4-directed immune checkpoint antibody                                         

 

 

Selleckchem的免疫檢查點單株抗體均採用重組抗體(recombinant antibody)的生產方式,更確保產品批次間的一致性,新品上市優惠中,請速洽群研科技想獨家優惠價!!

 

Catalog No.

Product Name

Information

A2006

Bevacizumab

Bevacizumab is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

A2007

Trastuzumab

Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.

A2008

Pertuzumab

Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.

A2009

Rituximab

Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.

A2010

Adalimumab

Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF, MW: 144.19 KD.

A2011

Sarilumab

Sarilumab is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD.

A2012

Tocilizumab

Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.

A2002

Nivolumab

Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

A2004

Atezolizumab

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

A2005

Pembrolizumab

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

A2000

Cetuximab

Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.

A2001

Ipilimumab

Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

 

 



     橘創整合行銷有限公司 』 建置